Product DevelopmentManagement noted that VTAMA AD approval could come a little early, representing potential sales upside.
Product InnovationNexplanon showed zero pregnancies in high BMI patients, raising the bar for generics and potentially exceeding $1.5 billion in peak sales.
Product PerformanceVtama's new product launch has reported good sales figures, boosting company performance.